67
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Postinfarction Metoprolol Treatment: Effects on Prognosis in Relation to Serum Cholesterol Concentrations

      research-article
      ,
      Cardiology
      S. Karger AG
      Metoprolol, Myocardial infarction, Prognosis, Cholesterol

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In a double-blind randomized study of 154 postmyocardial infarction patients assigned to metoprolol (100 mg twice daily) and 147 patients assigned placebo, the outcome during a 3-year follow-up according to serum cholesterol concentrations was evaluated. There was no indication that metoprolol influenced the total serum cholesterol concentration. The median cholesterol value at 3 months was 6.7 mmol/l. In patients with cholesterol >6.7 mmol/l, nonfatal reinfarctions were reduced in the metoprolol group (7 vs. 24%; p < 0.01). In patients with cholesterol > 6.7 mmol/l, mortality was lower in those treated with metoprolol (8 vs. 20%; p < 0.05). The beneficial effect of conventional postinfarction beta-blockade with metoprolol is independent of serum cholesterol concentration.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1987
          1987
          11 November 2008
          : 74
          : 6
          : 457-464
          Affiliations
          Department of Medicine, Karolinska Institutet, Danderyd Hospital, Danderyd, Sweden
          Article
          174238 Cardiology 1987;74:457–464
          10.1159/000174238
          3435909
          1e684c19-6a95-42af-9aef-f83304e7ef4a
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 21 July 1986
          : 25 December 1986
          Page count
          Pages: 8
          Categories
          Original Paper

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Cholesterol,Prognosis,Metoprolol,Myocardial infarction

          Comments

          Comment on this article